Literature DB >> 7000474

Cimetidine vs placebo in duodenal ulcer therapy. Six-week controlled double-blind investigation without any antacid therapy.

M J Collen, M R Hanan, J A Maher, M Rent, S E Stubrin, J F Arguello, L Gardner.   

Abstract

We studied the healing efficacy of cimetidine or placebo in 23 endoscopically proven duodenal ulcer outpatients in a randomized, controlled, prospective, double-blind trial. There were 11 patients in the cimetidine (1200 mg daily) treatment group and 12 patients in the placebo-treated group. No antacid was allowed, but a placebo antacid with no neutralizing capacity was given as needed for pain. The incidence of complete endoscopic healing at 2, 4, and 6 weeks was 54%, 63%, and 72% in the cimetidine-treated patients and 8%, 50%, and 67% in the placebo-treated patients. There was a statistically significant difference (P < 0.05) in complete duodenal ulcer healing between both treatment groups after 2 weeks of therapy, but there was no significant difference at the 4- and 6-week observation periods. The incidence of complete pain relief at 2 and 4 weeks was 64% and 82% in the cimetidine-treated patients and 67% and 75% in the placebo-treated patients. At 6 weeks of treatment there was no increase in the number of patients with complete pain relief in either group. There was no significant difference between the two groups in the incidence of ulcer pain relief at any of the three observation periods. Duodenal ulcer healing rates and duodenal ulcer pain relief were compared at 2, 4, and 6 weeks. There was no statistical association between ulcer healing and complete pain relief in the placebo treatment group at the 2-week evaluation period, but there was statistical association (P < 0.05) in the cimetidine treatment group at 2 weeks and both treatment groups at the 4- and 6-week evaluation periods. The results of this study demonstrate that in duodenal ulcer out-patients treated for 6 weeks: (1) cimetidine increases the incidence of duodenal ulcer healing during the first 2 weeks of treatment; (2) more than 50% of duodenal ulcers will spontaneously heal during a 4 to 6-week observation period which is not statistically modified by cimetidine treatment; (3) the complete relief of duodenal ulcer pain is not influenced by treatment with cimetidine when compared to placebo.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7000474     DOI: 10.1007/bf01345292

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  19 in total

1.  Factors influencing the rate of healing of gastric ulcers; admission to hospital, phenobarbitone, and ascorbic acid.

Authors:  R DOLL; F PYGOTT
Journal:  Lancet       Date:  1952-01-26       Impact factor: 79.321

2.  Healing of duodenal ulcer with an antacid regimen.

Authors:  W L Peterson; R A Sturdevant; H D Frankl; C T Richardson; J I Isenberg; J D Elashoff; J Q Sones; R A Gross; R W McCallum; J S Fordtran
Journal:  N Engl J Med       Date:  1977-08-18       Impact factor: 91.245

3.  Cimetidine in the treatment of duodenal ulcer: a multicenter double blind study.

Authors:  H J Binder; A Cocco; R J Crossley; W Finkelstein; R Font; G Friedman; J Groarke; W Hughes; A F Johnson; J E McGuigan; R Summers; R Vlahcevic; E C Wilson; D H Winship
Journal:  Gastroenterology       Date:  1978-02       Impact factor: 22.682

4.  The Veterans Administration Cooperative Study on Gastric Ulcer. 3. Site and size of the ulcer as determinants of outcome.

Authors:  D C Sun; S J Stempien
Journal:  Gastroenterology       Date:  1971-10       Impact factor: 22.682

5.  Long term cimetidine in the management of severe duodenal ulcer dyspepsia.

Authors:  G R Gray; I S Smith; I Mackenzie; G Gillespie
Journal:  Gastroenterology       Date:  1978-02       Impact factor: 22.682

6.  Treatment of duodenal ulcer with antacid and sulpiride. A double-blind controlled study.

Authors:  S K Lam; K C Lam; C L Lai; C K Yeung; L Y Yam; W S Wong
Journal:  Gastroenterology       Date:  1979-02       Impact factor: 22.682

7.  Comparison of two doses of cimetidine and placebo in the treatment of duodenal ulcer: a multicentre trial.

Authors: 
Journal:  Gut       Date:  1979-01       Impact factor: 23.059

8.  Gastric and duodenal ulcer healing under placebo treatment.

Authors:  U Scheurer; L Witzel; F Halter; H M Keller; R Huber; R Galeazzi
Journal:  Gastroenterology       Date:  1977-05       Impact factor: 22.682

9.  Cimetidine in the treatment of active duodenal and prepyloric ulcers.

Authors:  G Bodemar; A Walan
Journal:  Lancet       Date:  1976-07-24       Impact factor: 79.321

10.  Prevention by bedtime cimetidine of duodenal-ulcer relapse.

Authors:  W S Blackwood; D P Maudgal; T C Northfield
Journal:  Lancet       Date:  1978-03-25       Impact factor: 79.321

View more
  4 in total

1.  Refractory duodenal ulcers (nonhealing duodenal ulcers with standard doses of antisecretory medication).

Authors:  M J Collen; V J Stanczak; C A Ciarleglio
Journal:  Dig Dis Sci       Date:  1989-02       Impact factor: 3.199

2.  [Selective proximal vagotomy in the treatment of duodenal ulcer. Analysis of clinical results up to the 10th postoperative year].

Authors:  M Raab; H Stützer
Journal:  Langenbecks Arch Chir       Date:  1986

3.  Clinical and statistical issues in therapeutic equivalence trials.

Authors:  E Garbe; J Röhmel; U Gundert-Remy
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

4.  Misoprostol in the treatment of duodenal ulcer. A multicenter double-blind placebo-controlled study.

Authors:  S J Sontag; P A Mazure; J F Pontes; S G Beker; E Z Dajani
Journal:  Dig Dis Sci       Date:  1985-11       Impact factor: 3.199

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.